^
Association details:
| Biomarker: | NECTIN4 underexpression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Padcev (enfortumab vedotin-ejfv) (Microtubule inhibitor, Nectin-4-targeted antibody-drug conjugate) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Heterogeneity in Nectin-4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin.
Published date:
03/02/2021
Excerpt:
EV-resistant cell lines expressed decreased levels of Nectin-4....NECTIN4 expression is both necessary and sufficient for EV sensitivity in luminal and basal subtypes of urothelial bladder cancer cells....Results of this pre-clinical study suggest that sensitivity to EV is mediated by expression of NECTIN4...
DOI:
10.1200/JCO.2021.39.6_suppl.463
